Table 1 Baseline demographic and clinical characteristics of study patient

n = 36

n = 34

Age (y)

62.17 ± 6.21

62.97 ± 5.09

0.559

Male/Female

21/13

15/21

0.678

BMI

30.10 ± 4.04

29.83 ± 5.06

0.968

Current smokers, n (%)

8 (23.53%)

10 (27.8%)

0.684

Hypertension, n (%)

25 (75.53%)

26 (72.2%)

0.902

Diabetes mellitus, n (%)

13 (38.23%)

9 (25%)

0.233

Dyslipidemia, n (%)

26 (76.47%)

28 (77.8%)

0.896

Obesity, n (%)

17 (50%)

14 (38.9%)

0.349

Family history of IHD, n (%)

26 (76.5%)

27 (75%)

0.886

Concomitant medication:

   Statins (%)

25 (73.53%)

27 (75%)

0.888

   ACEIs/ARBs (%)

19(55.88%)

12 (33.33%)

0.150

   Diuretics (%)

6 (17.64%)

2 (5.56%)

0.112

   B-blockers (%)

19 (55.89%)

16 (44.4%)

0.338

   CCB-blockers (%)

10 (29.41%)

11 (30.56%)

0.917

   Aspirin (%)

13 (38.23%)

16 (44.45%)

0.598

Baseline systolic BP (mm/Hg)

125.2 ± 25.4

138.0 ± 20.8

0.203

Baseline diastolic BP (mm/Hg)

78.4 ± 11.7

75.9 ± 7.8

0.291

Baseline fasting glucose (mg/dl)

127.1 ± 52.8

118.9 ± 42.2

0.476

Baseline HbA₁C (%)

7.1 ± 1.7

6.8 ± 1.4

0.391

Baseline total cholesterol (mg/dl)

201.5 ± 53.1

198.8 ± 50.8

0.833

Baseline LDL Cholesterol (mg/dl)

117.5 ± 43.7

118.3 ± 47.1

0.945

Baseline HDL%

22.1 ± 4.6

26.0 ± 5.4

0.004

Baseline triglycerides (mg/dl)

189.5 ± 95.0

122.8 ± 56.5

0.001

Baseline hs-CRP (mg/dl)

1.84 ± 2.9

1.35 ± 1.6

0.616

Baseline endothelin(fmol/ml)

0.7 ± 2.6

1.4 ± 4.8

0.293

Baseline homocysteine (μmol/l)

9.2 ± 2.8

8.8 ± 3.1

0.486

Baseline renin (ng/ml/hr)

1.8 ± 3.4

1.5 ± 1.8

0.695

Baseline aldosteron (pg/ml)

7.4 ± 5.6

6.7 ± 4.5

0.590

Baseline urine cathacholamines (mg/24 h)

24.74 ± 22.4

19.5 ± 12.1

0.278